The review, published on 26 August 2026 by Xinyan Zou, Botao Zhang, Binxian Gu, Yong Gong, Yanchao Bai and Likui Zhang, focuses on NurA as a central component of a compact DNA end-resection machine. In archaeal cells, NurA works together with the HerA helicase and the Mre11-Rad50 complex. Their combined task is to process the broken ends of DNA and generate single-stranded DNA tails with a free 3′ end. These tails are essential substrates for homologous recombination, a repair pathway that uses an intact DNA molecule as a template to restore missing genetic information.

The first challenge after a double-strand break is not simply joining the broken ends. For homologous recombination to begin, the cell must carefully reshape the damaged DNA. One strand is progressively removed from each broken end, exposing the complementary strand as single-stranded DNA. This directional process, known as end resection, creates a molecular platform on which recombination proteins can assemble. The resulting 3′ single-stranded tails are particularly important because they can search for and pair with a matching sequence in an undamaged chromosome. NurA appears to perform a major part of the enzymatic cutting required to produce these tails, while HerA helps unwind the DNA and Mre11-Rad50 contributes to the initial recognition and processing of the break.

Structurally, archaeal NurA forms a toroidal dimer, producing a ring-shaped molecular assembly with a central channel. This architecture is more than a visual feature. A ring-shaped nuclease can help confine DNA within a defined catalytic environment, positioning the nucleic acid for controlled cleavage as it passes through or interacts with the channel. The dimeric arrangement also creates an extended surface for DNA binding and may help coordinate the movement of DNA with the action of the associated HerA helicase. According to the review, NurA and HerA can form a continuous channel, suggesting that DNA may be transferred directly from the helicase into the nuclease without freely diffusing into the surrounding cell.

NurA possesses two related but distinct catalytic capabilities. It can act as a 5′-to-3′ exonuclease, removing nucleotides sequentially from a DNA end, and it can also function as an endonuclease, cutting within a DNA strand rather than only at its terminus. These activities provide the enzyme with flexibility during repair. Exonucleolytic digestion can enlarge a resected region from an existing DNA end, while endonucleolytic cleavage may help initiate processing at particular DNA structures or positions. The balance between the two activities is likely to depend on the DNA substrate, the arrangement of the protein complex and the presence of partner enzymes, although the review emphasizes that important mechanistic questions remain unresolved.

The chemical engine behind NurA’s activity is a divalent metal ion. In particular, manganese ions, or Mn²⁺, are described as essential for catalysis. Like many nucleases, NurA is thought to use metal ions to organize the DNA substrate, activate water molecules and stabilize the negatively charged reaction intermediates that form when phosphodiester bonds are broken. The requirement for Mn²⁺ highlights the importance of the enzyme’s catalytic environment: without the appropriate metal cofactor, the chemical steps needed to cleave DNA cannot proceed efficiently. The review also summarizes the identification of amino acids that contribute to DNA binding and strand cleavage, helping define how NurA recognizes its substrate and positions the scissile phosphate bond for hydrolysis.

The NurA–HerA partnership is particularly significant because it links two physically different operations: DNA unwinding and DNA degradation. HerA is a helicase that uses energy from nucleotide hydrolysis to separate the two strands of the DNA duplex. NurA, positioned alongside it, can then process the exposed strand. Their continuous channel offers a possible explanation for how archaeal cells coordinate these reactions while minimizing the risk of uncontrolled DNA degradation. Rather than allowing a nuclease and helicase to operate independently, the paired system could guide DNA through a protected molecular corridor in which unwinding and resection are synchronized. The Mre11-Rad50 complex adds another layer of coordination by participating in the detection and early processing of broken chromosome ends.

This compact repair system is also important from an evolutionary perspective. NurA homologs are found across archaeal lineages and in some bacteria, but no NurA counterpart is known in eukaryotes. At the same time, eukaryotic cells possess more elaborate DNA end-resection pathways that perform related functions through different protein assemblies. The presence of NurA in archaea, together with its partnership with HerA and Mre11-Rad50, raises questions about how ancient DNA repair strategies were reorganized during the transition from prokaryotic ancestors to the first eukaryotic cells. The review presents NurA as a potentially valuable molecular marker for tracing which parts of double-strand break repair machinery were retained, replaced or lost during evolution.

Particular attention is drawn to the Asgard superphylum, a group of archaea considered especially relevant to studies of eukaryotic origins. Genomic surveys have identified widespread, previously uncharacterized NurA homologs in Asgard archaea. These proteins could reveal whether the structural and catalytic features observed in other archaeal NurA enzymes were already present in lineages related to the ancestors of eukaryotes. However, the review makes clear that Asgard-derived NurA proteins have not yet been experimentally characterized. Their biochemical activities, metal requirements, oligomeric states and interactions with HerA or Mre11-Rad50 remain open questions. Sequence similarity alone cannot establish whether these proteins possess the same dual nuclease activities or assemble into comparable DNA-processing channels.

The authors therefore identify structural biology and biochemistry as priorities for the next stage of research. Determining the three-dimensional structures of Asgard NurA proteins, ideally in complexes with DNA, HerA and metal ions, could show whether their active sites and central channels resemble those of previously studied archaeal enzymes. Complementary experiments could measure their exonuclease and endonuclease activities, define their substrate preferences and test how mutations in DNA-binding or catalytic residues affect repair-related reactions. Reconstituting the NurA–HerA–Mre11-Rad50 system outside the cell would be especially informative because it could reveal how each component contributes to end resection and whether the proteins form a stable, coordinated machine. By connecting molecular structure with biochemical function and evolutionary distribution, NurA research may help explain how cells across the domains of life learned to repair broken chromosomes—and why some lineages ultimately replaced this ancient strategy with entirely different molecular solutions.

Subject of Research: Archaeal NurA nuclease and its role in DNA double-strand break repair

Article Title: Archaeal NurA nuclease: structure, catalytic mechanism, and functional cooperation in DNA double-strand break repair

Article References: Zou, X., Zhang, B., Gu, B. et al. “Archaeal NurA nuclease: structure, catalytic mechanism, and functional cooperation in DNA double-strand break repair.” Applied Microbiology and Biotechnology (2026). https://doi.org/10.1007/s00253-026-14009-3

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00253-026-14009-3

Keywords: NurA nuclease; Archaea; DNA double-strand break repair; HerA helicase; Mre11-Rad50; homologous recombination; DNA end resection; Mn²⁺-dependent nuclease; Asgard archaea; molecular evolution

The work is supported by a renewed $3.2 million grant from the National Cancer Institute (National Institutes of Health). The project is building a new drug class intended to weaken cancer’s DNA double-strand break repair while enabling standard treatments to work at lower doses. The focus is lung cancer, where improved responses to radiotherapy could translate into better tumor control and reduced dose-related toxicity.

Led by Dr. Navnath Gavande (Wayne State University) and Dr. John Turchi (Indiana University School of Medicine), the team targets the Ku70/80 complex that sits at the start of the non-homologous end joining (NHEJ) pathway. In NHEJ, Ku recognizes DNA ends and recruits DNA-dependent protein kinase (DNA-PK) to initiate repair. By preventing Ku from binding damaged DNA, the researchers aim to shut down DNA-PK activation at its earliest functional step.

Unlike therapies that inhibit DNA-PK enzymatic activity directly, the Ku-targeted approach is designed as a “precision off-switch.” This structural strategy is intended to reduce unwanted effects on normal tissues by focusing on the DNA-binding event required for pathway activation. The idea is to block the recognition of broken DNA ends rather than merely interrupt the catalytic machinery downstream.

During the first funding phase, the group discovered and optimized small molecules that can enter cells, interfere with DNA-PK activation, disrupt NHEJ-mediated repair, and sensitize cancer cells to radiation and radiomimetic agents in preclinical models. With the renewed NIH support, the researchers plan to define which DNA damage contexts and tumor vulnerabilities yield the strongest therapeutic windows for Ku-binding inhibitors.

A central goal in the next stage is identifying combination opportunities. The team will search for DNA double-strand break repair settings in which Ku-DBi compounds create synthetic lethal interactions—situations where cancer cells die when two pathways are effectively compromised, but normal cells tolerate the disruption better.

“Our next phase will investigate various DNA double-strand break repair contexts to identify novel therapeutic combinations with Ku-DBi’s,” Gavande said. Alongside these biological studies, the program will continue medicinal chemistry optimization to improve in vivo potency and delivery.

The ultimate target is a first-in-class Ku70/80 DNA-binding inhibitor platform that enhances radiotherapy effectiveness by undermining DNA repair dependence. If successful, the approach could offer a more selective route to radiosensitization across hard-to-treat solid tumors beyond lung cancer.

Subject of Research: Ku70/80 DNA-binding inhibitors to inhibit DNA-PK activation and radiosensitize lung cancer
Article Title: Discovery and development of Ku-targeted small molecule inhibitors: A novel mechanism of DNA-PK inhibition
News Publication Date:
Web References: http://www.gavandelab.com/
References: National Cancer Institute/NIH award R01CA247370
Image Credits:

Keywords: cancer, DNA damage, DNA repair, DNA-PK, Ku70/80, NHEJ, radiotherapy, lung cancer, radiosensitization

DNA double-strand breaks (DSBs) represent some of the most lethal forms of genomic damage, necessitating precise and efficient repair mechanisms to maintain genomic integrity. Among the repair pathways, NHEJ stands as a predominant mechanism in mammalian cells, rapidly ligating broken DNA ends. DNA-dependent protein kinase (DNA-PK), a central enzyme in NHEJ, coordinates the detection and processing of DSBs to facilitate repair. However, the precise molecular players that coordinate DNA-PK activity with downstream effectors had remained incompletely characterized until now, with CRTC2 emerging as a key modulator in this process.

The research team led by Zou, Yao, Dong, and colleagues employed a combination of biochemical assays, advanced imaging, and cancer immunology models to unravel the role of CRTC2 phosphorylation by DNA-PK. Their initial studies revealed that upon DNA damage, CRTC2 undergoes phosphorylation catalyzed by DNA-PK, a modification crucial for its translocation to sites of DNA repair. This phosphorylation event effectively converts CRTC2 from a cytoplasmic transcriptional coactivator to a critical participant in the DNA repair machinery, positioning it as an indispensable element in the maintenance of genomic stability.

Mechanistically, phosphorylated CRTC2 serves as a scaffold that promotes the assembly of NHEJ factors at the damaged DNA loci. By interacting with core NHEJ components, CRTC2 facilitates efficient ligation of DNA ends, thereby accelerating the repair process. The team’s experiments demonstrated that loss or mutation of DNA-PK phosphorylation sites on CRTC2 resulted in markedly impaired NHEJ activity, leading to an accumulation of unrepaired DSBs and increased genomic instability—a hallmark of many cancers.

Intriguingly, beyond its canonical role in DNA repair, CRTC2 phosphorylation appears to impact the tumor microenvironment’s immune landscape. The researchers observed that enhanced NHEJ activity via phosphorylated CRTC2 correlates with a suppression of antitumor immune responses. This unexpected finding suggests a new paradigm where DNA repair mechanisms influence immune evasion by tumors, providing a molecular link between genome maintenance and immune regulation. The relocation of phosphorylated CRTC2 to repair complexes not only repairs DNA damage but concomitantly inhibits pathways involved in activating immune cells against tumor cells.

Further investigations into the immune consequences of CRTC2’s function revealed that its activity dampens cytotoxic T cell infiltration and interferon signaling within tumors, key components of effective antitumor immunity. By promoting DNA repair and limiting immune activation, tumors may exploit the DNA-PK/CRTC2 axis to foster an environment conducive to survival and growth despite host immune surveillance efforts. This dual role places CRTC2 at the crossroads of cancer cell-intrinsic and -extrinsic survival strategies.

The therapeutic implications of these findings are profound. Targeting DNA-PK or the phosphorylation sites on CRTC2 could disrupt this axis, sensitizing tumors to DNA damage-inducing agents while concurrently restoring robust antitumor immune function. Such dual modulation holds promise for overcoming resistance to conventional therapies and immunotherapies alike. Indeed, preliminary data from the study indicate that pharmacological inhibition of DNA-PK synergizes with immune checkpoint blockade to suppress tumor progression in murine models.

From a broader perspective, the study sheds light on the sophisticated interplay between DNA repair pathways and immune regulation. It challenges prior assumptions that DNA repair components solely serve genome maintenance roles and positions them as active participants in shaping the immune microenvironment. This insight encourages a reevaluation of DNA repair proteins as multifunctional hubs, integrating cellular responses to genotoxic stress with immune modulation cues.

Technically, the elucidation of CRTC2’s phosphorylation dynamics was enabled by state-of-the-art phosphoproteomics, coupled with CRISPR-mediated gene editing to generate precise phospho-mutant models. These cutting-edge approaches validated the necessity of specific phosphorylation residues for CRTC2’s function in DNA repair and immune suppression. Advanced microscopy techniques allowed visualization of CRTC2 redistribution into DNA repair foci, confirming its spatial dynamics in real-time cellular contexts.

Notably, the study addresses potential concerns regarding specificity by demonstrating that CRTC2’s role is distinct from other CRTCs, highlighting the unique regulation mediated by DNA-PK-dependent phosphorylation. This specificity opens avenues for targeted drug design, minimizing off-target effects that could arise from broader CRTC inhibition. The researchers postulate that therapeutic agents designed to disrupt CRTC2 phosphorylation or its interaction with NHEJ components could selectively sensitize cancer cells without compromising normal tissue repair.

Moreover, this work triggers a cascade of questions ripe for future investigation. For example, how does CRTC2-mediated immune suppression integrate with other known tumor immune evasion mechanisms? What are the implications for tumor heterogeneity and resistance to various DNA damaging agents? Could CRTC2 functions vary across different cancer types or stages, and how might this impact patient stratification in clinical settings? These considerations underscore the study’s foundational role in sparking novel hypotheses.

In conclusion, Zou, Yao, Dong and their collaborators have unveiled a critical nexus between DNA repair and tumor immunity through the phosphorylation of CRTC2 by DNA-PK. This discovery contributes a compelling new layer to our understanding of cancer biology and offers a promising molecular target for innovative therapies aimed at enhancing genome stability while reinvigorating antitumor immune responses. The fusion of molecular repair biology with immuno-oncology encapsulated in this research exemplifies the future of precision oncology, where treatment strategies are informed by the intricate molecular choreography within cancer cells.

As scientific exploration continues to decode the complexity of DNA repair and immune evasion, the DNA-PK/CRTC2 axis stands out as a beacon of transformative potential. With ongoing advancements in genomic editing and immunotherapy modalities, harnessing this newly identified pathway could revolutionize how clinicians approach the formidable challenge of cancer treatment. The study is a testament to the innovative spirit driving modern biomedical science, paving the way for breakthroughs that could save countless lives while deepening our grasp of cellular resilience and vulnerability.

Subject of Research:
DNA-PK-mediated phosphorylation of CRTC2 and its role in promoting non-homologous end joining (NHEJ) DNA repair and suppression of antitumor immunity.

Article Title:
DNA-PK-mediated CRTC2 phosphorylation promotes NHEJ and suppresses antitumor immunity via relocation to repair complexes.

Article References:
Zou, F., Yao, Z., Dong, X. et al. DNA-PK-mediated CRTC2 phosphorylation promotes NHEJ and suppresses antitumor immunity via relocation to repair complexes. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73228-4

Image Credits:
AI Generated

MYC’s traditional role has been well-characterized: as a transcription factor in the cell nucleus, it orchestrates the expression of genes that govern cellular proliferation and metabolism. This relentless drive for growth, however, is a double-edged sword. Rapid proliferation frequently induces DNA damage and replication stress, threatening genomic integrity. Intriguingly, researchers have discovered that beyond switching genes on and off, a phosphorylated form of MYC specifically targets sites of DNA double-strand breaks, physically recruiting DNA repair proteins to maintain tumor cell survival.

The study highlights serine 62 phosphorylation of MYC as a critical modification that enables its association with damaged DNA. This post-translational modification marks a departure from MYC’s canonical transcriptional activities, positioning it directly at the loci of DNA lesions. By facilitating the assembly of repair complexes, MYC empowers cancer cells to resist the cytotoxic effects of chemotherapy and radiation, both of which traditionally inflict lethal DNA damage.

This newly identified function poses profound implications for oncologic therapies. Since MYC activity assists tumor cells in rapidly repairing DNA, it effectively diminishes the destructive impact of genotoxic treatments. Consequently, tumors with elevated MYC levels often exhibit striking resilience, leading to treatment failure and poor prognoses. Pancreatic cancer, notable for its high MYC expression and dismal survival rates, exemplifies a malignancy where targeting this repair axis could transform clinical outcomes.

The researchers conducted an elaborate series of experiments using patient-derived pancreatic cancer cells and extensive tumor data analysis. They established a strong correlation between heightened MYC activity, increased DNA repair proficiency, and aggressive tumor behavior. Tumors expressing high levels of phosphorylated MYC demonstrated enhanced survival under chemotherapy-induced DNA damage, unveiling a molecular mechanism underlying therapeutic resistance in notoriously intractable cancers.

Perhaps most striking is the paradigm shift this research offers in targeting MYC. Historically branded “undruggable” due to its structural complexity and ubiquity in normal cellular processes, MYC presents formidable challenges for selective inhibition. However, the discrete role of MYC in DNA repair—distinct from its broader transcriptional responsibilities—offers a precision target. By disrupting MYC’s recruitment to DNA breaks without dismantling its normal functions, future therapies could sensitize tumors to DNA-damaging agents while sparing healthy tissue.

OHSU is already pioneering investigation into this therapeutic avenue through clinical trials of a novel MYC inhibitor named OMO-103. Conducted under a “window of opportunity” framework, this trial aims to assess the drug’s impact on MYC activity and DNA repair dynamics in patients with advanced pancreatic cancer. Such studies represent the vanguard of precision oncology, potentially overcoming long-standing barriers that have hindered effective MYC targeting.

This research not only sheds light on MYC’s multifaceted role in cancer biology but also redefines fundamental concepts of tumor adaptability. By co-opting DNA repair mechanisms, MYC enables cancer cells to thrive in the face of profound genotoxic stress—a hallmark of both tumor development and treatment regimens. Understanding these intricate molecular relationships provides a blueprint for novel intervention strategies designed to dismantle tumor defenses.

Given the pressing clinical need, particularly in malignancies refractory to current therapies, this discovery serves as a beacon of hope. It underscores the necessity of integrating molecular insights into therapeutic design, aiming not just to halt tumor growth but to thwart their ability to survive assault. As MYC’s non-canonical function in DNA repair comes into sharper focus, the oncology community moves closer to breakthroughs that could substantially prolong and improve patient lives.

In summary, the elucidation of MYC’s role in facilitating DNA repair under genotoxic stress elucidates a vital mechanism behind chemotherapy and radiation resistance. This insight presents a fertile ground for developing targeted inhibitors that could potentially tip the balance in favor of treatment success, particularly against aggressive tumors like pancreatic cancer. Continued research and clinical validation hold promise for revolutionizing how we combat one of the deadliest forms of cancer.

Subject of Research: Role of MYC in DNA repair and cancer cell survival under genotoxic stress

Article Title: MYC serine 62 phosphorylation promotes its association with DNA double strand breaks to facilitate repair and cell survival under genotoxic stress

News Publication Date: 15-May-2026

Web References: http://dx.doi.org/10.1101/gad.352832.125

Image Credits: OHSU/Christine Torres Hicks

Keywords: Pancreatic cancer, Chemotherapy, DNA damage, MYC protein, DNA repair, Genotoxic stress, Cancer resistance, Molecular oncology, Serine 62 phosphorylation, Tumor survival mechanisms

DNA damage is a ubiquitous threat posed by both endogenous metabolic processes and external insults such as ultraviolet radiation and chemical agents. Left unchecked, DNA lesions can accumulate, leading to mutations, cell dysfunction, or death, ultimately manifesting in degenerative diseases and premature aging. The zebrafish, with its transparent embryos and genetic tractability, offers an exquisite system to explore the molecular mechanisms underlying tissue homeostasis and genomics under stress.

The research delineates how Mytho/Phaf1 functions intricately within the DNA damage response (DDR) network. Employing advanced genetic manipulation techniques, the authors inactivated the Mytho/Phaf1 gene orthologs in zebrafish, observing a pronounced accumulation of DNA double-strand breaks over time. This disruption triggered activation of canonical DDR pathways, including ATR and ATM kinase signaling cascades, yet proved insufficient in fully mitigating genomic instability, resulting in marked tissue degeneration across multiple organ systems.

Notably, Mytho/Phaf1 appears to engage directly with chromatin remodeling complexes that facilitate access of DDR proteins to sites of DNA lesions. By modulating chromatin structure, Mytho/Phaf1 enhances the recruitment of repair complexes, accelerating lesion recognition and repair fidelity. The absence of functional Mytho/Phaf1 compromises this chromatin accessibility, leading to persistent DNA damage foci and triggering apoptotic pathways, which explain the observed deterioration in tissue integrity.

Furthermore, the study reveals that Mytho/Phaf1 has an essential role beyond DNA repair itself, influencing cellular senescence and inflammatory responses—a phenomenon often linked to chronic tissue degeneration. In the Mytho/Phaf1-deficient zebrafish, increased expression of pro-inflammatory cytokines and markers of senescence were detected, suggesting that Mytho/Phaf1 may act as a modulator of the senescence-associated secretory phenotype (SASP), thereby curbing inflammatory cascades initiated by damaged or aged cells.

From a developmental biology perspective, the absence of Mytho/Phaf1 perturbed normal zebrafish organogenesis, particularly affecting tissues with high proliferative demands, such as the neural and muscular systems. This observation underscores the protein complex’s significance in developmental timing and cellular turnover, critical factors in organismal health and longevity.

Integral to the experimental approach was the use of CRISPR-Cas9 mediated gene editing, which allowed precise abrogation of Mytho/Phaf1 expression. Coupled with high-throughput imaging and single-cell RNA sequencing, the team comprehensively mapped the spatial and temporal patterns of DNA damage, repair dynamics, and gene expression changes induced by Mytho/Phaf1 loss. These multilayered analyses provided unparalleled insights into the molecular choreography orchestrated by Mytho/Phaf1 in vivo.

The implications of these findings extend far beyond zebrafish biology. Given the evolutionary conservation of many DDR components across vertebrates, including humans, the elucidation of Mytho/Phaf1’s role opens new avenues for understanding human diseases characterized by genome instability, such as cancer, neurodegeneration, and premature aging syndromes. Targeting Mytho/Phaf1 or its regulatory pathways could pave the way for novel therapeutic strategies aimed at enhancing DNA repair capacity and tissue regeneration.

Critically, the study also highlights the interconnectedness of DNA repair mechanisms with cellular metabolism and stress responses. The researchers observed metabolic shifts in Mytho/Phaf1-deficient zebrafish, including altered mitochondrial function and reactive oxygen species (ROS) accumulation, which are closely linked to oxidative DNA damage. This integration of metabolic and genomic stability networks is a frontier area of research with profound consequences for biology and medicine.

Methodologically, the study set a high standard by deploying multi-omics approaches to unravel the complex biological functions of Mytho/Phaf1. Proteomic analyses revealed direct interactors and downstream effectors of the complex, implicating it in pathways governing autophagy, apoptosis, and cell cycle checkpoints. Such comprehensive profiling contributes to a holistic understanding of cellular quality control systems.

The discovery prompts intriguing questions about whether Mytho/Phaf1 function can be modulated pharmacologically and whether such interventions could delay degenerative processes or improve outcomes following genotoxic stress. Further research in mammalian models will be crucial to translate these insights into clinical applications, potentially targeting age-related diseases or enhancing tissue repair after injury.

This study adds to the growing compendium of evidence positioning zebrafish as an indispensable model for genetic and cellular investigations into human health. By leveraging the unique advantages of this organism, the authors have uncovered novel biological functions that may hold keys to unlocking strategies for genome preservation and tissue rejuvenation.

In conclusion, the identification of Mytho/Phaf1 as a central player in preventing DNA damage accumulation and maintaining tissue integrity represents a landmark advancement in biomedicine. It provides a fresh paradigm linking chromatin regulation, DNA repair, metabolic health, and inflammation in a unified framework essential for organismal vitality. This work heralds a promising future where understanding the molecular guardians of the genome may empower us to combat degenerative diseases and extend healthy lifespan.

As science progresses rapidly, studies like this exemplify the profound impact of interdisciplinary research in decoding life’s complexity. The intersections of genetics, molecular biology, developmental science, and bioinformatics converge to illuminate new pathways toward preserving health and combating disease. Mytho/Phaf1 emerges from this cutting-edge research not just as a molecular entity but as a beacon guiding future exploration into cellular resilience and longevity.

With the publication of this seminal work in Cell Death Discovery, the field stands poised to delve deeper into the mysteries of genome maintenance, leveraging the lessons learned from a tiny freshwater fish to illuminate vast biomedical horizons. Mytho/Phaf1 is now established as an essential guardian of genomic fidelity, whose function resonates across species, promising breakthroughs in understanding and potentially treating a swath of human pathologies rooted in DNA damage and tissue degradation.

Subject of Research: The role of Mytho/Phaf1 in preventing DNA damage and tissue degeneration using the zebrafish (Danio rerio) model.

Article Title: Mytho/Phaf1 is required to prevent DNA damage and tissue degeneration in Danio rerio.

Article References:
Pagliarusco, T., Franco-Romero, A., Terrin, F. et al. Mytho/Phaf1 is required to prevent DNA damage and tissue degeneration in Danio rerio. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03106-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03106-x